Clinical Trial Update: Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial of vemurafenib/cobimetinib with or without bevacizumab in stage IV BRAFV600 mutant melanoma was terminated; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)
• Cobimetinib (Cotellic) (cobimetinib)
• Vemurafenib (Zelboraf) (vemurafenib)

Snippet

Sponsor: Melanoma Research Foundation Breakthrough Consortium | Conditions: Melanoma, Metastatic Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2017-06-23